Key Market Indicator:
F&G: 23
25.215,70 NASDAQ · 47.521,00 DOW · 6.798,75 S&P · 4.239,07 Gold · 63,49 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
DE0005664809
Filter zurücksetzen
© EQS Newswire
12.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec receives milestone payment from Bristol Myers Squibb following IND acceptance in strategic protein degradation partnership
Article
News Preview
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec   Hamburg, Germany, 12 November 2025: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WK......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Article
News Preview
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populationsFDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE / ACCESS Newswire / November 12, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, W...
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Continued strong execution on strategic priorities
Article
News Preview
  Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand; Just – Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business Strong scientific advancements of co-developed asset pipeline: Expecting up to four mo......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
05.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Weiterhin konsequente Umsetzung strategischer Prioritäten
Article
News Preview
  Konzernumsatz von 535,1 Mio. € (-7,1 %); Discocery & Preclinical Development-Segment ("D&PD", -12,3 %) mit weiterhin zurückhaltender Nachfrage; Just – Evotec Biologics ("JEB", +11,3 %) übertrifft Erwartungen; weiter beschleunigtes Wachstum außerhalb der Kooperationen mit Sandoz und dem US-amerikanischen Verteidigungsministerium Depa......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
05.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Article
News Preview
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD businessStrong scientific advancements of co-developed asset pipeline: Expecting u...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties
Article
News Preview
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules   Transaction showcases Evotec’s unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing techn......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen
Article
News Preview
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen an einem Portfolio von bis zu 10 Biosimilar-Molekülen   Die Transaktion unterstreicht Evotecs einzigartige Fähigkeiten Kunden durch ihre kontinuierliche Produktionsstechn......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Article
News Preview
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technologyAccelerated implementation of strategy through better monetization of technology and transitioning to an asset-lighter business modelAgreement includes approximately US$ 350 m in cash for...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.10.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Bekanntgabe der Ergebnisse für die ersten neun Monate 2025 am 05. November 2025
Article
News Preview
Hamburg, 29. Oktober 2025: Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) veröffentlicht am Mittwoch, 05. November 2025, ihre Zwischenmitteilung für die ersten neun Monate 2025. In einer Telefonkonferenz in englischer Sprache werden die Ergebnisse und Schwerpunkte aus dem Beri......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.10.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE to announce results for the first nine months 2025 on 05 November 2025
Article
News Preview
Hamburg, Germany, 29 October 2025: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025. The Company is going to hold a conference call to discuss the results as well as provide an update ......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.10.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
Article
News Preview
HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025.The Company is going to hold a conference call to discuss the results as well as provi...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.10.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
Article
News Preview
  Fortschritte in der präklinischen Pipeline zur Bekämpfung neurodegenerativer Erkrankungen Evotec erhält eine Zahlung von 25 Mio. US$, um die weitere Entwicklung gemeinsamer Programme zu unterstützen   Hamburg, 27. Oktober 2025: Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 5664......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
27.10.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
Article
News Preview
  Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs   Hamburg, Germany, 27 October 2025: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced t......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.10.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Article
News Preview
Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that the...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Deutliche Fortschritte bei Strategieumsetzung
Article
News Preview
Strategie für nachhaltiges profitables Wachstum verläuft planmäßig mit Verbesserung des Umsatzmixes und über dem Plan liegenden Kostensenkungen Das bisher als „Shared R&D” bezeichnete Berichtssegment wurde in „Discovery & Preclinical Development” („D&PD“) umbenannt, um den strategischen Fokus besser widerzuspiegeln Konzernumsatz......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Strong progress on strategy execution
Article
News Preview
  Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development (“D&PD”) to better reflect strategic focus Group revenues of € 371.2 m (-5%); D&PD (-11%) continu......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.08.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Article
News Preview
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductionsReporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect strategic focusGroup revenues of € 371.2 m (-5%); D&PD (-11%) continues...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Bekanntgabe der Ergebnisse für das erste Halbjahr 2025 am 13. August 2025
Article
News Preview
Hamburg, 06. August 2025: Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) veröffentlicht am Mittwoch, 13. August 2025, ihren Halbjahresbericht für die ersten sechs Monate 2025. In einer Telefonkonferenz in englischer Sprache werden die Ergebnisse und Schwerpunkte aus dem B......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE to announce first half-year results 2025 on 13 August 2025
Article
News Preview
Hamburg, Germany, 06 August 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025. The Company is going to hold a conference call to discuss the results as well as provide an u......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.08.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE to announce first half-year results 2025 on 13 August 2025
Article
News Preview
HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.The Company is going to hold a conference call to discuss the results as well as p...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site
Article
News Preview
  Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just – Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just – Evotec Biologics’ advanced continuous manufacturing technology ......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec und Sandoz entwickeln ihre strategische Partnerschaft weiter und vereinbaren einen möglichen Verkauf des Just – Evotec Biologics Standorts in Toulouse
Article
News Preview
  Evotec SE und Sandoz AG haben ein nicht-bindendes Term Sheet über den geplanten Verkauf von Just – Evotec Biologics EU in Toulouse an Sandoz unterzeichnet Im Rahmen der vorgeschlagenen Vereinbarung würde Evotec ihre Ressourcen zur Herstellung von Biosimilars übertragen, um Sandoz die Produktion von Biosimilar-Arzneimitteln unter Verwend......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site
Article
News Preview
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014   Ad hoc: Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces the sig......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE und Sandoz AG planen möglichen Verkauf von Just – Evotec Biologics Standort Toulouse
Article
News Preview
Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014   Ad hoc: Evotec SE und Sandoz AG planen möglichen Verkauf von Just – Evotec Biologics Standort Toulouse Hamburg – Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) gibt die Unterze......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
Article
News Preview
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a considerati...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Article
News Preview
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to SandozUnder the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technologyThe deal terms in...
Themefolio
Profiler
Peergroup
© EQS Newswire
21.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec passt Umsatzprognose an und bestätigt Gewinnprognose; profitablerer Umsatzmix erwartet
Article
News Preview
  Erfolgreiche Umsetzung der neuen Strategie für nachhaltiges und profitables Wachstum führt zu einem veränderten Umsatzmix, getrieben durch die starke Nachfrage nach Evotecs differenzierten Plattformen Margenstarke Technologie-Lizenzeinnahmen werden sich voraussichtlich stärker als erwartet auswirken Deutliche Kostenoptimierung übert......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec adjusts revenue guidance and confirms profit guidance anticipating a more profitable revenue mix
Article
News Preview
  Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec’s differentiated platforms High-margin technology license revenues expected to have a stronger impact than anticipated Significant cost optimization in excess of initial targets from Priority Reset......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
Article
News Preview
Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014   Ad hoc: Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose Hamburg – Die Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) gibt bekannt, dass sie ihre Umsatzprognose für d......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE adjusts revenue guidance while confirming profit guidance
Article
News Preview
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014   Ad hoc: Evotec SE adjusts revenue guidance while confirming profit guidance Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has updated its reve......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
Article
News Preview
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platformsHigh-margin technology license revenues expected to have a stronger impactthan anticipatedSignificant cost optimization in excess of initial targets from Priority ResetShared R&D base...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.07.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
Article
News Preview
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged.For the current fiscal year, the Company...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis von akutem Nierenversagen
Article
News Preview
  NURTuRE-AKI ist eine neue Beobachtungsstudie, die longitudinale biologische Proben und klinische Daten von Patienten mit akutem Nierenversagen (Acute Kidney Injury, „AKI") sammelt. Sie wurde im Rahmen eines Forschungskonsortiums unter Leitung von Kidney Research UK entwickelt. Die Studie konzentriert sich auf 3 Kohorten: AKI nach Herzop......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec joins NURTuRE-AKI consortium to gain multi-omics-based molecular understanding of acute kidney injury
Article
News Preview
  NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury (“AKI”) patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chr......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.06.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury
Article
News Preview
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UKThe study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chroni...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.06.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Ergebnisse der Hauptversammlung 2025
Article
News Preview
Alle Tagesordnungspunkte angenommen Unter dem Motto „Pioneering Drug Discovery – Wegweisende Arzneimittelforschung“ stellte CEO Dr. Christian Wojczewski die aktuelle Situation und den strategischen Ausblick von Evotec vor 46,45 % des eingetragenen Grundkapitals vertreten Hamburg, 03. Juni 2025: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/Te......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.06.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Results of the Annual General Meeting 2025
Article
News Preview
All agenda items adopted Under the topic “Pioneering Drug Discovery” CEO Dr Christian Wojczewski presented Evotec’s current situation and strategic outlook 46.45% of the registered share capital represented Hamburg, Germany, 03 June 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that ......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.05.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec receives $ 2.5 m grant to generate next generation tuberculosis treatments
Article
News Preview
  Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies.   ......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.05.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec erhält Fördergelder in Höhe von 2,5 Mio. USD für die Entwicklung von Tuberkulose-Therapien der nächsten Generation
Article
News Preview
  Die Gates Foundation unterstützt Evotec mit einem Zuschuss von 2,5 Mio. USD zur Generierung entscheidender Daten für die Entwicklung neuer Kombinationstherapien gegen Tuberkulose Die Kooperation setzt die erfolgreiche Partnerschaft zur Bewertung neuer Therapieansätze fort, die auf eine Verkürzung der Behandlungsdauer und die Überwindung......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.05.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Article
News Preview
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies. HAMBURG, DE / ACCESS N...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.05.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Weichenstellung für Wachstum 2025 in schwierigem Marktumfeld
Article
News Preview
  Konzernumsatz von 200 Mio. €, im Einklang mit Prognose; Shared R&D mit ähnlichem Trend wie im Jahr 2024; Just - Evotec Biologics mit anhaltender Wachstumsdynamik Signifikante Fortschritte in der strategischen Partnerschaft mit Bristol Myers Squibb im Bereich gezielter Proteinabbau Strategie baut auf führender Rolle in Technologi......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.05.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Paving the way for 2025 growth in soft market environment
Article
News Preview
  Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just – Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation partnership with Bristol Myers Squibb Strategy building on technology and science leadership: Focus on high-growth, high-value segme......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.05.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Article
News Preview
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentumStrong progress in strategic protein degradation partnership with Bristol Myers SquibbStrategy building on technology and science leadership: Focus on high-growth, high-value segments, simplif...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Bekanntgabe der Ergebnisse für das erste Quartal 2025 am 6. Mai 2025
Article
News Preview
Hamburg, 29. April 2025: Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) veröffentlicht am Dienstag, 6. Mai 2025, ihre Zwischenmitteilung über das erste Quartal 2025. In einer Telefonkonferenz in englischer Sprache werden die Ergebnisse und Schwerpunkte aus dem Berichtszeitraum näher erläutert. Außer......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE to announce results for the first quarter 2025 on 6 May 2025
Article
News Preview
Hamburg, Germany, 29 April 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025
Article
News Preview
HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The c...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec verkündet starke Fortschritte in strategischer Kollaboration mit Bristol Myers Squibb im Bereich Protein Degradation
Article
News Preview
  Wichtige wissenschaftliche Erfolge treiben die Erweiterung der Pipeline von Molecular Glue Degraders für ungedeckte medizinische Bedürfnisse voran Leistungs- und programmabhängige Zahlungen an Evotec in Höhe von insgesamt 75 Mio. US$   Hamburg, 24. April 2025: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE000......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb
Article
News Preview
  Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs Performance-based and program-based payments of in total US$ 75 m to Evotec   Hamburg, Germany, 24 April 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced furt......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
Article
News Preview
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needsPerformance-based and program-based payments of in total US$ 75 m to Evotec HAMBURG, DE / ACCESS Newswire / April 24, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced further signi...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024
Article
News Preview
    Evotec fokussiert sich auf wegweisende Wirkstoffforschung und zeigt Weg zu nachhaltigem, profitablem Wachstum auf Strategie baut auf Vorreiterrolle in Technologie- und Wissenschaft auf, konzentriert sich auf wachstumsstarke, hochwertige Segmente, vereinfacht das Geschäftsmodell und fördert operative Exzellenz Starke Umsatz- und E......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results
Article
News Preview
  Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence Strong Q4 2024 revenue and EBITDA results in spite of ch......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results
Article
News Preview
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growthStrategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellenceStrong Q4 2024 revenue and EBITDA results in spite of challenging market c...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE to announce results for financial year 2024 on 17 April 2025
Article
News Preview
Hamburg, Germany, 10 April 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025. The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review process. The confe......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Bekanntgabe der Ergebnisse für das Geschäftsjahr 2024 am 17. April 2025
Article
News Preview
Hamburg, 10. April 2025: Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) veröffentlicht am Donnerstag, 17. April 2025, ihren Bericht für das Geschäftsjahr 2024. In einer Telefonkonferenz in englischer Sprache werden die Ergebnisse des Geschäftsjahres 2024 präsentiert und erläutert. Außerdem wird ein ......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.04.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025
Article
News Preview
HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025.The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review proc...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec gibt wichtige Fortschritte in der Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
Article
News Preview
  Laufende strategische Partnerschaft bringt gemeinsame Pipeline in der  Neurodegenerationsforschung voran Evotec erhält eine Zahlung von 20 Millionen Dollar, um die Forschung weiter voranzutreiben   Hamburg, 04 März 2025: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute einen we......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Article
News Preview
  Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research   Hamburg, Germany, 04 March 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced another major accomplishment in its long......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.03.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Article
News Preview
Ongoing strategic partnership advances joint pipeline in neurodegeneration researchEvotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced another major accomplishment in its long-standing n...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.02.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec announces change in Management Board
Article
News Preview
  Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025   Hamburg, Germany, 26 February 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Financia......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.02.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec gibt Veränderung im Vorstand bekannt
Article
News Preview
  Laetitia Rouxel tritt mit Wirkung zum 28. Februar 2025 als Chief Financial Officer zurück Paul Hitchin mit Wirkung zum 1. März 2025 zum Nachfolger als Chief Financial Officer berufen   Hamburg, 26. Februar 2025: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute bekannt, dass ihr......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.